VYNE Therapeutics Inc. was granted an extension until September 7, 2026, to regain compliance with Nasdaq's minimum bid price requirement after failing to meet it by March 10, 2026. If the stock price remains below $1.00, it risks delisting unless compliance is achieved within the new timeframe.